- Home
- GENC vs ACHV Comparison
GENC vs ACHV Comparison
Compare GENC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GENC | ACHV |
|---|---|---|
| Founded | N/A | N/A |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 231.0M |
| IPO Year | 1995 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GENC | ACHV |
|---|---|---|
| Price | $15.14 | $4.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $16.00 | $15.50 |
| AVG Volume (30 Days) | 25.3K | ★ 645.3K |
| Earning Date | 05-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 8.08 | ★ 17.33 |
| EPS | ★ 0.23 | N/A |
| Revenue | ★ $48,943,000.00 | N/A |
| Revenue This Year | $125,306.93 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $66.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.80 | $1.84 |
| 52 Week High | $17.40 | $6.03 |
Technical Indicators
Market Signals| Indicator | GENC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 39.62 |
| Support Level | $14.94 | $4.11 |
| Resistance Level | $16.00 | $4.30 |
| Average True Range (ATR) | 0.68 | 0.25 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 68.84 | 43.10 |
Price Performance
Historical ComparisonAbout GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.